MRK
Another one bites the cytokine
Merck just dropped positive topline data from the Phase 3 ATLAS-UC induction-only study of tulisokibart (MK-7240), its anti-TL1A antibody being tested in moderately to severely active ulcerative colitis. The big headline: the study met its primary endpoint — clinical remission by the Modified Mayo Score at week 12 — plus key secondary endpoints.
Why investors should care
This is one of those biotech moments where the vibe matters almost as much as the numbers. Merck says there were no safety concerns, which is exactly the kind of line you want to hear when a drug is trying to graduate from “promising science project” to “actual commercial franchise.”
And this isn’t just a one-off science fair ribbon. Merck says tulisokibart has the broadest development program in the anti-TL1A class, with seven indications in play. In other words, this could be more than a one-disease story if the data keep holding up.
The next lap
The company plans to present these results alongside the ongoing induction and maintenance study at an upcoming scientific congress, then take the package to regulators. That means today’s win is important, but it’s still a checkpoint — not the finish line.
Big picture: Merck keeps trying to prove it’s not just the Keytruda show. A successful new immunology asset like tulisokibart would help widen the pipeline and give investors one more reason to believe the post-Keytruda era doesn’t have to be a cliff jump.